Cellular Therapy Research Program

Barbara Savoldo, MD, PhD, conducts basic research.
Dr. Savoldo examining a specimen as part of an experiment in the Savoldo Lab
Dr. Barbara Savoldo’s research is on T-cell therapy in the fight against cancer; T-Cell Therapy re-engineers a type of white blood cell called a T-cell, so that the cell can recognizes and kills cancerous cells. This re-engineering inserts a gene into the T-cell using the ability of certain viruses to insert their genes into host cells.Dr. Savoldo's research is primarily on Hodgkin lymphoma and non-Hodgkin lymphoma, two types of cancer marked by uncontrolled growth of certain white blood cells. She plans to open trials for patients with leukemia. She would like to expand this study to include patients with solid tumors, like neuroblastoma and brain tumors.

 

In addition to her interest in the preclinical development of cancer immunotherapy approaches for hematological and solid tumors, Dr. Savoldo provide support in writing protocols, developing standard operating procedures and training T-cell processing staff operating in the facility in order to implement T-cell therapy clinical trials at the University of North Carolina, Chapel Hill. Dr. Savoldo is also the assistant director of the Lineberger Immunotherapy Program. 

Open Clinical Trials

DiagnosisAge RangeStudy Title
ALL, Immune System Diseases, Immunoproliferative Disorders  1 Year and Older Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Patient with Acute Lymphoblastic Leukemia
Lymphomas 3 years and Older Phase I Study of Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)

For a list of publications by Dr. Savoldo, please click here.